SALVAT Has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
10/10/2007 11:08:29 AM
BARCELONA, Spain--(BUSINESS WIRE)--This double-blind, placebo-controlled and multi-center Phase II trial includes 332 patients with Overactive Bladder (OAB) and has been conducted at 77 sites in 11 countries (US, Germany, Spain, The Netherlands, Czech Republic, Hungary, Poland, Russia, South Africa, New Zealand and Australia). The company expects to report the results of this trial during November.
comments powered by